TABLE OF CONTENT: 1. Introduction 1.1. Research Scope 1.2. Market Segmentation 1.3. Research Methodology 1.4. Definitions and Assumptions 2. Executive Summary 3. Market Dynamics 3.1. Market Drivers 3.2. Market Restraints 3.3. Market Opportunities 4. Key Insights 4.1. Pipeline Analysis 4.2. Overview of Regulatory Scenario by Key Regions 4.3. Key Industry Developments 4.4. Number (Estimated) of Primary Immunodeficiency (PI) Patients by Key Countries 4.5. Overview of Reimbursement Scenario 5. Global Intravenous Immunoglobulins Market Analysis, Insights and Forecast, 2015-2025 5.1. Key Findings /Summary 5.2. Market Analysis, Insights and Forecast – By Indication 5.2.1. Primary Immunodeficiency 5.2.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 5.2.3. Guillain-Barré Syndrome (GBS) 5.2.4. Immune Thrombocytopenic Purpura (ITP) 5.2.5. Multifocal Motor Neuropathy (MMN) 5.2.6. Others 5.3. Market Analysis, Insights and Forecast – By Form 5.3.1. Liquid 5.3.2. Lyophilized 5.4. Market Analysis, Insights and Forecast – By End User 5.4.1. Hospitals 5.4.2. Clinics 5.4.3. Homecare 5.5. Market Analysis, Insights and Forecast – By Region 5.5.1. North America 5.5.2. Europe 5.5.3. Asia Pacific 5.5.4. Latin America 5.5.5. Middle East & Africa 6. North America Intravenous Immunoglobulins Market Analysis,Insights and Forecast, 2015-2026 6.1. Key Findings / Summary 6.2. Market Analysis – By Indication 6.2.1. Primary Immunodeficiency 6.2.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 6.2.3. Guillain-Barré Syndrome (GBS) 6.2.4. Immune Thrombocytopenic Purpura (ITP) 6.2.5. Multifocal Motor Neuropathy (MMN) 6.2.6. Others 6.3. Market Analysis – By Form 6.3.1. Liquid 6.3.2. Lyophilized 6.4. Market Analysis – By End User 6.4.1. Hospitals 6.4.2. Clinics 6.4.3. Homecare 6.5. Market Analysis – By Country 6.5.1. U.S. 6.5.2. Canada 7. Europe Intravenous Immunoglobulins Market Analysis, Insights and Forecast, 2015-2026 7.1. Key Findings / Summary 7.2. Market Analysis – By Indication 7.2.1. Primary Immunodeficiency 7.2.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 7.2.3. Guillain-Barré Syndrome (GBS) 7.2.4. Immune Thrombocytopenic Purpura (ITP) 7.2.5. Multifocal Motor Neuropathy (MMN) 7.2.6. Others 7.3. Market Analysis – By Form 7.3.1. Liquid 7.3.2. Lyophilized 7.4. Market Analysis – By End User 7.4.1. Hospitals 7.4.2. Clinics 7.4.3. Homecare 7.5. Market Analysis – By Country/ Sub-Region 7.5.1. U.K. 7.5.2. Germany 7.5.3. France 7.5.4. Spain 7.5.5. Italy 7.5.6. Scandinavia 7.5.7. Rest of Europe 8. Asia Pacific Intravenous Immunoglobulins Market Analysis, Insights and Forecast, 2015-2026 8.1. Key Findings / Summary 8.2. Market Analysis – By Indication 8.2.1. Primary Immunodeficiency 8.2.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 8.2.3. Guillain-Barré Syndrome (GBS) 8.2.4. Immune Thrombocytopenic Purpura (ITP) 8.2.5. Multifocal Motor Neuropathy (MMN) 8.2.6. Others 8.3. Market Analysis – By Form 8.3.1. Liquid 8.3.2. Lyophilized 8.4. Market Analysis – By End User 8.4.1. Hospitals 8.4.2. Clinics 8.4.3. Homecare 8.5. Market Analysis – By Country/ Sub-Region 8.5.1. Japan 8.5.2. China 8.5.3. India 8.5.4. Australia 8.5.5. Southeast Asia 8.5.6. Rest of Asia Pacific 9. Latin America Intravenous Immunoglobulins Market Analysis,Insights and Forecast, 2015-2026 9.1. Key Findings / Summary 9.2. Market Analysis – By Indication 9.2.1. Primary Immunodeficiency 9.2.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 9.2.3. Guillain-Barré Syndrome (GBS) 9.2.4. Immune Thrombocytopenic Purpura (ITP) 9.2.5. Multifocal Motor Neuropathy (MMN) 9.2.6. Others 9.3. Market Analysis – By Form 9.3.1. Liquid 9.3.2. Lyophilized 9.4. Market Analysis – By End User 9.4.1. Hospitals 9.4.2. Clinics 9.4.3. Homecare 9.5. Market Analysis – By Country/ Sub-Region 9.5.1. Brazil 9.5.2. Mexico 9.5.3. Rest of Latin America 10. Middle East &Africa Intravenous Immunoglobulins Market Analysis, Insights and Forecast,2015-2026 10.1. Key Findings / Summary 10.2. Market Analysis –By Indication 10.2.1. Primary Immunodeficiency 10.2.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 10.2.3. Guillain-Barré Syndrome (GBS) 10.2.4. Immune Thrombocytopenic Purpura (ITP) 10.2.5. Multifocal Motor Neuropathy (MMN) 10.2.6. Others 10.3. Market Analysis –By Form 10.3.1. Liquid 10.3.2. Lyophilized 10.4. Market Analysis – By End User 10.4.1. Hospitals 10.4.2. Clinics 10.4.3. Homecare 10.5. Market Analysis – By Country/ Sub-Region 10.5.1. GCC Countries 10.5.2. South Africa 10.5.3. Rest of Middle East & Africa 11. Competitive Analysis 11.1. Key Industry Developments 11.2. Global Market Share Analysis (2018) 11.3. Competition Dashboard 11.4. Comparative Analysis – Major Players 11.5. Company Profiles (Overview, Products& Services, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability)) 11.5.1. Shire (Takeda Pharmaceutical Company Limited) 11.5.2. CSL Behring 11.5.3. Grifols, S.A. 11.5.4. Kedrion S.p.A 11.5.5. Octapharma 11.5.6. Bio Products Laboratory Ltd. 11.5.7. Biotest AG 11.5.8. China Biologic Products Holdings, Inc. 11.5.9. LFB SA 11.5.10. Shanghai RAASBlood Products Co., Ltd. 12. Strategic Recommendations

Shire (Takeda Pharmaceutical Company Limited) CSL Behring Grifols, S.A. Kedrion S.p.A Octapharma Bio Products Laboratory Ltd. Biotest AG China Biologic Products Holdings, Inc. LFB SA Shanghai RAAS Blood Products Co., Ltd.